Company news

BioInvent International AB news in 2026

BioInvent International AB's news releases, calls and decks from 2026, newest first.

View company

BioInvent International to present BI-1808 data in platinum-resistant recurrent ovarian cancer at ESMO 2026

October 18, 2026

BioInvent to Host a KOL Event in Stockholm on June 11, 2026, to Discuss Updated BI-1206 & BI-1808 Data in Hematology

June 1, 2026

BioInvent to Present Clinical Data on FcγRIIB Antibody BI-1206 Triplet Combination Therapy with rituximab and Calquence(R) in Relapsed/Refractory NHL at EHA 2026

May 12, 2026

BioInvent International AB: Interim Report January - March 2026

April 29, 2026

BioInvent International AB Publishes Annual Report 2025

March 31, 2026

BioInvent Achieves Phase 3 Milestone for HMI-115 in Endometriosis

March 26, 2026

Notice to Annual General Meeting in BioInvent International AB

March 24, 2026

BioInvent International AB: Year-End Report January 1 - December 31, 2025

February 26, 2026

Invitation to Presentation of BioInvent's Year-End Report 2025

February 26, 2026

BioInvent Announces Nomination of Two New Board Members Ahead of 2026 Annual General Meeting

February 23, 2026

BioInvent Reports Promising Data from Ongoing Phase 2a study for BI-1808 with KEYTRUDA(R) (pembrolizumab) in Recurrent Ovarian Cancer

January 5, 2026

Calls in 2026

Decks in 2026